Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LUMINA 3: Rilzabrutinib in Warm Autoimmune Hemolytic Anemia
NCT07086976Phase 3Recruiting
- Sponsor
- Sanofi
- Start
- Aug 2025
- Primary completion
- May 2028
- Modality
- Small Molecules
- Countries
- 18
01
Overview
Phase 3, randomised, double-blind trial in warm autoimmune hemolytic anemia (wAIHA) comparing rilzabrutinib with placebo (2 arms). Primary endpoint: Durable Hemoglobin Response at 24 weeks. Started Aug 2025; status: recruiting.
02
Drugs
rilzabrutinib
03
Conditions
warm autoimmune hemolytic anemia (wAIHA)
Beyond the preview
Go deeper on NCT07086976.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07086976.